Payment overview · 2025
General Payments
$549.75
38 reported records · 12 companies
Healthcare provider profile · identity verified
Leah Stone
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAWRENCEBURG, TN · NPI 1013375484
Verified facts
What the public records show
CMS Open Payments records show Leah Stone received $549.75 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.62 | 34.1% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.11 | 12.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.34 | 9.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.15 | 6.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.89 | 6.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.05 | 6.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.94 | 5.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.29 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.26 | 4.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.71 | 4.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.49 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.90 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.75 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $187.62 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.17 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.34 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 87 |
| Methylprednisolone | Methylprednisolone | 97 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 54 |
| Gabapentin | Gabapentin | 92 | 36 |
| Omeprazole | Omeprazole | 89 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 69 | 44 |
| Metformin Hcl | Metformin Hcl | 67 | 30 |
| Prednisone | Prednisone | 60 | 53 |
| Lisinopril | Lisinopril | 59 | 36 |
| Azithromycin | Azithromycin | 55 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 32 |
| Furosemide | Furosemide | 48 | 27 |
| Trazodone Hcl | Trazodone Hcl | 45 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 44 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 26 |
| Carvedilol | Carvedilol | 41 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 26 |
| Benazepril Hcl | Benazepril Hcl | 34 | 18 |
| Pregabalin | Pregabalin | 34 | 16 |
| Potassium Chloride | Potassium Chloride | 33 | 21 |
| Cefdinir | Cefdinir | 32 | 29 |
| Jardiance | Empagliflozin | 32 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | 15 |
| Simvastatin | Simvastatin | 31 | 21 |
| Ramipril | Ramipril | 29 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 21 |
| Fluconazole | Fluconazole | 28 | 19 |
| Mounjaro | Tirzepatide | 28 | 12 |
| Ondansetron Odt | Ondansetron | 28 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 17 |
| Gemfibrozil | Gemfibrozil | 26 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 17 |
| Farxiga | Dapagliflozin Propanediol | 24 | 16 |
| Methocarbamol | Methocarbamol | 24 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | 13 |
| Cephalexin | Cephalexin | 23 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 16 |
| Losartan Potassium | Losartan Potassium | 22 | 16 |
| Meloxicam | Meloxicam | 22 | 16 |
| Sertraline Hcl | Sertraline Hcl | 22 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Clarithromycin | Clarithromycin | 21 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Nystatin | Nystatin | 21 | 16 |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Dexamethasone | Dexamethasone | 19 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | 12 |
| Allopurinol | Allopurinol | 18 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Famotidine | Famotidine | 17 | 15 |
| Benzonatate | Benzonatate | 16 | 15 |
| Buspirone Hcl | Buspirone Hcl | 14 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Naproxen | Naproxen | 13 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.75 · 38 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Korlym, MINIMED 780G, NURTEC ODT, Omnipod, Ozempic, TRELEGY ELLIPTA, VRAYLAR, YUPELRI, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error